Ondrej Fiala

Ondrej Fiala

Pilsen, PL, Czech Republic

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 158 publications

Machine learning-integrated explainable artificial intelligence for survival prediction in urothelial carcinoma with enfortumab vedotin: an exploratory real-world analysis.

Machine learning-integrated explainable artificial intelligence for survival prediction in urothelial carcinoma with enfortumab vedotin: an exploratory real-world analysis.

Journal: Expert opinion on biological therapy

Published: August 29, 2026

Concurrent Adenoid Cystic/Basal Cell Carcinoma and Acinar Adenocarcinoma of the Prostate: Comprehensive Molecular Analysis of Both Tumor Component.

Concurrent Adenoid Cystic/Basal Cell Carcinoma and Acinar Adenocarcinoma of the Prostate: Comprehensive Molecular Analysis of Both Tumor Component.

Journal: International journal of surgical pathology

Published: August 17, 2026

GPNMB expression in clear cell papillary renal cell tumour: Limited specificity and a potential diagnostic pitfall in clear cell renal neoplasms.

GPNMB expression in clear cell papillary renal cell tumour: Limited specificity and a potential diagnostic pitfall in clear cell renal neoplasms.

Journal: Annals of diagnostic pathology

Published: July 01, 2026

Darolutamide versus abiraterone acetate-based triplets in patients with hormone-sensitive prostate cancer: real-world, head-to-head comparison from the ARON-3 study.

Darolutamide versus abiraterone acetate-based triplets in patients with hormone-sensitive prostate cancer: real-world, head-to-head comparison from the ARON-3 study.

Journal: Minerva urology and nephrology

Published: June 23, 2026

Nivolumab in previously treated metastatic renal cell carcinoma: real-world data from the Czech Republic and Slovakia.

Nivolumab in previously treated metastatic renal cell carcinoma: real-world data from the Czech Republic and Slovakia.

Journal: Frontiers in immunology

Published: April 22, 2026

Real-world prognostic assessment of the HERO score in metastatic urothelial carcinoma treated with enfortumab vedotin (ARON-2EV study).

Real-world prognostic assessment of the HERO score in metastatic urothelial carcinoma treated with enfortumab vedotin (ARON-2EV study).

Journal: ESMO open

Published: April 21, 2026

Role of Local Treatment to the Prostate in Patients With de Novo Low-volume Metastatic Hormone-sensitive Prostate Cancer Receiving Androgen Receptor Pathway Inhibitors.

Role of Local Treatment to the Prostate in Patients With de Novo Low-volume Metastatic Hormone-sensitive Prostate Cancer Receiving Androgen Receptor Pathway Inhibitors.

Journal: European urology open science

Published: March 12, 2026

Early systemic inflammatory-metabolic trajectory phenotypes are associated with survival outcomes in metastatic renal cell carcinoma treated with nivolumab.

Early systemic inflammatory-metabolic trajectory phenotypes are associated with survival outcomes in metastatic renal cell carcinoma treated with nivolumab.

Journal: Scientific reports

Published: March 10, 2026

Baseline Disease Characteristics and Platinum Sensitivity as Predictors of Outcomes in Sequential Therapy with Platinum-Based Chemotherapy, Avelumab Maintenance, and Enfortumab Vedotin in Advanced Urothelial Carcinoma (ARON-2EV Study).

Baseline Disease Characteristics and Platinum Sensitivity as Predictors of Outcomes in Sequential Therapy with Platinum-Based Chemotherapy, Avelumab Maintenance, and Enfortumab Vedotin in Advanced Urothelial Carcinoma (ARON-2EV Study).

Journal: Targeted oncology

Published: February 20, 2026

Prognostic Role of Serum Neuron-Specific Enolase at Baseline and its Early Dynamics in Metastatic Castration-Resistant Prostate Cancer Treated With Androgen Receptor Signaling Inhibitors.

Prognostic Role of Serum Neuron-Specific Enolase at Baseline and its Early Dynamics in Metastatic Castration-Resistant Prostate Cancer Treated With Androgen Receptor Signaling Inhibitors.

Journal: The Prostate

Published: February 17, 2026

Real-world incidence of G3-G4 adverse events in patients with advanced renal cell carcinoma receiving immune-combinations (ARON-1).

Real-world incidence of G3-G4 adverse events in patients with advanced renal cell carcinoma receiving immune-combinations (ARON-1).

Journal: Frontiers in immunology

Published: February 05, 2026

Enfortumab vedotin in ECOG-PS 2 advanced urothelial carcinoma patients: a real-world study from the ARON-2EV project.

Enfortumab vedotin in ECOG-PS 2 advanced urothelial carcinoma patients: a real-world study from the ARON-2EV project.

Journal: BMC cancer

Published: January 19, 2026

Showing 1-12 of 158

Last Updated: 09/26/2026